Search Results - "Montoro, JB"

Inhaled Tobramycin in Non-Cystic Fibrosis Patients with Bronchiectasis and Chronic Bronchial Infection with Pseudomonas aeruginosa by Drobnic, M Estrella, Sune, Pilar, Montoro, J Bruno, Ferrer, Adelaida, Orriols, Ramon

“…BACKGROUND: Non—cystic fibrosis (CF) patients with bronchiectasis usually develop chronic bronchial infection with Pseudomonas aeruginosa (PA) that is related…”
Get full text

4CPS-247 Initiatives to improve the management of patients with hereditary angioedema by hospital pharmacy by Montoro Ronsano, JB, Martínez Sesmero, JM, Lleonart Bellfill, R

“…Background and ImportanceHereditary angioedema (HAE) is a rare, hereditary disease with a negative impact on the quality of life of patients. The increase in…”
Get full text

HSD96 Burden of Patient Journey in the Management of Alpha-1 Antitrypsin Deficiency in Spain by Martínez-Sesmero, JM, Cabeza, J, Pablo, Q, Campins, L, Roch, M, Zamora, D, Montoro, JB

Get full text

4CPS-062 Rituximab pharmacokinetics characterisation in plasma and urine in a patient with nephotic syndrome by Larrosa García, M, Agraz Pamplona, I, Bury Macias, RP, Sanz Martínez, MT, Perurena Prieto, J, Martinez Gallo, M, Hernandez Gonzalez, M, Anguita Domingo, D, Montoro Ronsano, JB, Gorgas Torner, MQ

“…Background and importanceRituximab (RTX) is a monoclonal antibody used to treat various conditions including glomerular diseases (GD) as an off-label…”
Get full text

4CPS-146 Sublingual and enteric tacrolimus whole blood levels in an intensive care unit by Doménech, L, Guiu Segura, JM, Montoro Ronsano, JB

“…BackgroundTacrolimus is an immunosuppressive agent with a narrow therapeutic range (5–15 ng/ml for solid organ transplants). Achieving and maintaining…”
Get full text

4CPS-119 ‘Real world’ experience of tofacitinib and baricitinib in the treatment of rheumatoid arthritis: effectiveness and safety evaluation by Garcia Garcia, S, Cardona Pascual, I, Larrosa Garcia, M, Montoro Ronsano, JB, Caparros Ruiz, R, Alonso Martinez, C, Vidal Otero, J, Gamarra Calvo, S, Gomez Domingo, MR, Alerany Pardo, C

“…Background and importanceTofacitinib and baricitinib are oral Janus kinase inhibitors (JKi) approved for the treatment of rheumatoid arthritis (RA), offering…”
Get full text

4CPS-033 Off-label use of nebulised aztreonam lysine in patients with chronic gram negative bacterial lung colonisation by Garcia Garcia, S, Cardona Pascual, I, Revilla López, E, Larrosa García, M, Alonso Martinez, C, Vidal Otero, J, Alerany Pardo, C, Cantos Gil, L, Granollers Rabal, P, Gomez Domingo, MR, Montoro Ronsano, JB

“…Background and importanceAztreonam lysine inhalation solution (AZLI) is approved for nebulised treatment (nebT) of pulmonary Pseudomonas aeruginosa infections…”
Get full text

4CPS-151 Influence of the route and pharmaceutical preparation in intra-patient variability of tacrolimus serum levels in the liver transplant patient by Garcia Garcia, S, Dopazo Taboada, C, Aller Hernández, MB, Bilbao Aguirre, I, Pericas Bosch, E, Montoro Ronsano, JB

“…BackgroundIn the earliest stages, immunosuppressive therapy in liver transplant patients (LTP) is targeted to avoid acute rejection, to preserve graft survival…”
Get full text

4CPS-150 Evaluation of intra-patient variability of the tacrolimus plasmatic levels in different periods after liver transplant by Garcia Garcia, S, Dopazo Taboada, C, Aller Hernández, MB, Bilbao Aguirre, I, Pericas Bosch, E, Montoro Ronsano, JB

“…BackgroundImmunosuppressive therapy in liver transplant patients (LTP) is divided into several temporary periods after surgery. The priority is to avoid acute…”
Get full text

4CPS-148 Analysis of intra-patient variability of plasmatic levels of tacrolimus in early maintenance of renal post-transplant by Garcia Garcia, S, Oleas Vega, DS, Aller Hernández, MB, Torres Rodriguez, I, Chamoun Huacón, BO, Pericas Bosch, E, Montoro Ronsano, JB

“…BackgroundTacrolimus is a calcineurinic inhibitor characterised by a narrow therapeutic window and high variability of plasmatic levels.PurposeTo assess the…”
Get full text

4CPS-149 Evaluation of intra-patient variability of the tacrolimus plasmatic levels in the different periods of the kidney post-transplant by Garcia Garcia, S, Oleas Vega, DS, Aller Hernández, MB, Torres Rodriguez, I, Chamoun Huacón, BO, Pericas Bosch, E, Montoro Ronsano, JB

“…BackgroundThe management of immunosuppression in kidney transplant (KT) is divided into: induction from 0 to 3 months, early maintenance (EM) from 3 to 6…”
Get full text

CP-067 Effectiveness and safety of rituximab in autoimmune kidney disease after 12 months of follow-up by Roch, M, Rivera-Sanchez, L, Segarra, A, Montoro, JB

“…BackgroundRituximab, a monoclonal antibody against the CD20 receptor of the lymphocyte membrane, is increasingly used off-label in autoimmune kidney disease…”
Get full text

4CPS-129 Evaluation of the real infusion time of intravenous immunoglobulin and influential factors in routine clinical practice analysis by Martinez, C Alonso, Morante, E Serramontmany, Izquierdo, A Roig, Ortin, E Lozano, Gomila, M Garau, Sebastia, L Betriu, Ronsano, JB Montoro

“…BackgroundIntravenous immunoglobulin (IVIG) is the standard of care for humoral immunodeficiencies (HID) and several systemic autoimmune diseases. Its chronic…”
Get full text

Effects of competition and its outcome on serum testosterone, cortisol and prolactin by Suay, F, Salvador, A, González-Bono, E, Sanchı́s, C, Martı́nez, M, Martı́nez-Sanchis, S, Simón, V.M, Montoro, J.B

“…In various species, competitive encounters influence hormonal responses in a different way depending on their outcome, victory or defeat. This study aimed to…”
Get full text

CP-044 Appropriateness of albumin trealment in non-critical and non-oncohaematological hospitalised patients by Roig, R Juvany, Pitarch, E Esteve, García, P Latorre, Talaveron, J Llop, Maroto, MT Perez, Sanchez, L Rivera, Blanco, JL Perez, Moral, L Domenech, Masanes, R Jodar, Ronsano, JB Montoro

“…This abstract was published in error and withdrawn at the author’s request…”
Get full text

Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study by Ponseti, José M., Azem, Jamal, Fort, José M., Codina, Agustín, Montoro, J. Bruno, Armengol, Manuel

“…Thirteen patients with myasthenia gravis, unresponsive to prednisone and cyclosporin after thymectomy, received KF506 (tacrolimus) for 12 months, at starting…”
Get full text

4CPS-072 Real-world experience in haemophilia B patients after switching to fix extended half-life using pharmacokinetic population software and monocompartmental model by Juárez-Giménez, JC, Benítez-Hidalgo, O, Romero-Garrido, JA, Mateos-Salillas, C, González-Piñeiro, S, Montoro-Ronsano, JB

“…Background and ImportanceNew strategies have been developed for the prophylactic treatment of patients with haemophilia B (HB) such as extended half-life…”
Get full text

Recommendations for the Implementation of the Self-Administration of Alpha-1 Antitrypsin by Torres-Durán, María, López-Campos, José Luis, Calle Rubio, Myriam, Montero-Martínez, Carmen, Priegue Carrera, Ana, Amaro Rodríguez, Rosanel, Barrecheguren, Miriam, Barrio Guirado, María Ángeles, Callejas-González, Francisco Javier, Casas-Maldonado, Francisco, Diab-Cáceres, Layla, García-Meseguer, Pilar, Hernández-Pérez, José María, Lázaro-Asegurado, Lourdes, Martínez-González, Cristina, Martínez Rivera, Carlos, Michel, Francisco Javier, Montoro-Ronsano, José-Bruno, Sánchez, Raquel, Ortiz-Pica, Marta, Parra, Isabel, Quintero García, José Pablo, Ruiz-Serrano-de la Espada, María Del Rosario, Tortajada-Goitia, Begoña, Miravitlles, Marc

“…Administration of exogenous alpha-1 antitrypsin (AAT) is the only specific therapy for the management of pulmonary morbidity in patients with AAT deficiency…”
Get full text

Modulating effects of intravenous immunoglobulins on serum cytokine levels in patients with primary hypogammaglobulinemia by Ibáñez, Cristina, Suñé, Pilar, Fierro, Ana, Rodríguez, Santiago, López, Maite, Alvarez, Antonio, De Gracia, Javier, Montoro, José-Bruno

“…Intravenous immunoglobulins (IVIG) have usually been administered for replacement therapy of humoral immunodeficiencies, but their use in treating other…”
Get full text

4CPS-176 Electrolyte disturbances in premature infants with intrauterine growth restriction receiving parenteral nutrition by Gómez-Ganda, L, Parramón-Teixidó, CJ, Garcia-Palop, B, Linés-Palazón, M, Castillo-Salinas, F, Blanco-Grau, A, Montoro-Ronsano, JB, Clemente-Bautista, S

“…Background and importanceIntrauterine growth restriction (IUGR) in neonates can promote the occurrence of electrolyte disturbances. Therefore, some authors…”
Get full text